Metformina + Sitagliptina Teva

Metformin hydrochloride and sitagliptin, the active ingredient in Metformina + Sitagliptina Teva, is a biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels when used with diet and exercise.

GNH USA supplies Metformina + Sitagliptina Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets, and reliable delivery timelines.

Metformina + Sitagliptina Teva is used in the treatment of type 2 diabetes mellitus, an endocrine disorder characterized by insulin resistance and impaired glucose regulation.

- Type 2 diabetes mellitus: improves overall glycemic control, reducing HbA1c levels. - Inadequate control on metformin alone: adds an additional glucose‑lowering effect. - Combined with lifestyle modifications: helps patients achieve target blood‑glucose goals.

Metformina + Sitagliptina Teva may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, usually transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas requiring immediate medical attention.

Before initiating therapy, clinicians should consider several safety factors.

- Renal function: assess creatinine clearance and adjust dose if needed. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia or severe infection. - Pregnancy and lactation: evaluate risk‑benefit; data are limited. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Metformina + Sitagliptina Teva can interact with several medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Phenformin or other contraindicated biguanides: risk of severe lactic acidosis. - Insulin or sulfonylureas: may cause severe hypoglycemia. - Renal dialysis: metformin accumulation risk.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metformin plasma concentrations. - Thiazide diuretics: can affect glucose control. - Iodinated contrast media: temporary discontinuation of metformin is recommended before and after imaging.